Concepts (54)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Risk Reduction Behavior | 2 | 2014 | 174 | 0.830 |
Why?
|
| Neoplasms | 3 | 2014 | 1667 | 0.640 |
Why?
|
| Terminology as Topic | 1 | 2013 | 141 | 0.420 |
Why?
|
| Survival Rate | 1 | 2014 | 1056 | 0.390 |
Why?
|
| Adaptation, Psychological | 1 | 2014 | 447 | 0.380 |
Why?
|
| Electronic Health Records | 1 | 2013 | 374 | 0.340 |
Why?
|
| Obesity | 1 | 2013 | 1076 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 468 | 0.200 |
Why?
|
| Breast Neoplasms | 3 | 2015 | 1536 | 0.190 |
Why?
|
| Receptor, ErbB-2 | 2 | 2015 | 129 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 2 | 2015 | 104 | 0.150 |
Why?
|
| Immunoconjugates | 1 | 2015 | 26 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 508 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 129 | 0.120 |
Why?
|
| Diet, Reducing | 1 | 2013 | 46 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 498 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 370 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 511 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2013 | 183 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 475 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 261 | 0.100 |
Why?
|
| Communication | 1 | 2013 | 329 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 425 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 442 | 0.090 |
Why?
|
| Humans | 7 | 2015 | 68618 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 767 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1070 | 0.070 |
Why?
|
| Epothilones | 2 | 2015 | 2 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 536 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 800 | 0.050 |
Why?
|
| Female | 4 | 2015 | 38074 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 111 | 0.030 |
Why?
|
| Polyneuropathies | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 129 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2015 | 16 | 0.030 |
Why?
|
| Pruritus | 1 | 2015 | 35 | 0.030 |
Why?
|
| Aged | 3 | 2015 | 14862 | 0.030 |
Why?
|
| Trastuzumab | 1 | 2014 | 17 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 274 | 0.030 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2015 | 41 | 0.030 |
Why?
|
| Carboplatin | 1 | 2014 | 59 | 0.030 |
Why?
|
| Alopecia | 1 | 2015 | 45 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 349 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2015 | 7029 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 951 | 0.030 |
Why?
|
| Middle Aged | 3 | 2015 | 21147 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 446 | 0.030 |
Why?
|
| Adult | 3 | 2015 | 21403 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 682 | 0.030 |
Why?
|
| Male | 1 | 2014 | 37321 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1174 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 756 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 2093 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 4848 | 0.020 |
Why?
|